title: Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.
abstract: BACKGROUND
  The high incidence of locoregional recurrences and distant metastases after curative surgery for gastric cancer calls for improved locoregional control and systemic adjuvant treatment.
  
  
  METHODS
  In a randomized clinical trial on adjuvant FAM2 chemotherapy, quality of surgery was evaluated by comparing surgical and pathology data. Univariate and multivariate analysis was made to evaluate the effect of prognostic factors on survival and time of recurrence in relation to patients, tumor, and therapy.
  
  
  RESULTS
  Of 314 patients randomized from 28 European institutions, 159 comprised the control and 155 the FAM2 group. After a median follow-up of 80 months, no statistically significant difference was found between survivals. However, for recurrence time, treated patients had a significant advantage over controls (p = 0.02). At univariate analysis, statistically significant differences in survival and time to progression emerged for T, N, disease stage and "adequacy" of surgery. The multivariate analysis retained preoperative Hb level, T, N, and "adequacy" of surgery for time of survival; and T, N, "adequacy" of surgery and adjuvant chemotherapy for recurrence time.
  
  
  CONCLUSIONS
  Disease stage is the most important prognostic factor. "Adequate" surgery has an important effect. Adjuvant FAM2 delayed time of recurrence, but did not influence overall survival.
authors.affiliation: Istituto di Clinica Chirurgica II, Università di Padova, Padua, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Lise
authors.forename: D
authors.initials: D
authors.lastname: Nitti
authors.forename: A
authors.initials: A
authors.lastname: Marchet
authors.forename: T
authors.initials: T
authors.lastname: Sahmoud
authors.forename: N
authors.initials: N
authors.lastname: Duez
authors.forename: A
authors.initials: A
authors.lastname: Fornasiero
authors.forename: J G
authors.initials: JG
authors.lastname: dos Santos
authors.forename: R
authors.initials: R
authors.lastname: Labianca
authors.forename: P
authors.initials: P
authors.lastname: Lasser
authors.forename: M
authors.initials: M
authors.lastname: Gignoux
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil